RxDoctor Payments Data

Natasha Joshi, DO

Pulmonary Disease · Loveland, CONPI 1740419993

Payments from drug & device makers

$487in general payments, 2019–2025

Across 23 payments — averaging $21.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$181
  • Sunovion Pharmaceuticals Inc.$97
  • Mylan Specialty L.p.$68
  • Novartis$42
  • Pulmonx Corporation$28
  • Grifols USA, LLC$24
  • plus $47 from 3 others

What the payments were for

  • Food & beverage$47598%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$487 in reported general payments places this provider in the 35th percentile of 248 pulmonary disease providers in Colorado.

See all pulmonary disease providers in Colorado

Medicare billing

Part B allowed, 2024
$41,707
Medicare patients
201
Services billed
405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter145$155,374
Spiriva RespimatTiotropium Bromide114$93,404
Breztri AerosphereBudesonide/Glycopyr/Formoterol74$77,461
Stiolto RespimatTiotropium Br/Olodaterol Hcl45$48,134
SymbicortBudesonide/Formoterol Fumarate76$29,852
Combivent RespimatIpratropium/Albuterol Sulfate22$28,460
Advair HfaFluticasone Propion/Salmeterol44$27,127
Incruse ElliptaUmeclidinium Bromide42$25,906
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr30$25,467
Spiriva HandihalerTiotropium Bromide17$21,891
Fluticasone-SalmeterolFluticasone Propion/Salmeterol90$18,053
Breo ElliptaFluticasone/Vilanterol16$14,014
Wixela InhubFluticasone Propion/Salmeterol53$12,331
Albuterol Sulfate HfaAlbuterol Sulfate332$10,726
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate36$6,624

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$181$169,998181 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 248 pulmonary disease providers in Colorado.

Other pulmonary disease in Loveland

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →